Documentdetail
ID kaart

oai:pubmedcentral.nih.gov:9052...

Onderwerp
Review
Auteur
Hasan-Abad, Amin Moradi Mohammadi, Mohsen Mirzaei, Hamed Mehrabi, Mohsen Motedayyen, Hossein Arefnezhad, Reza
Langue
en
Editor

BioMed Central

Categorie

Clinical and Molecular Allergy : CMA

Jaar

2022

vermelding datum

16-08-2024

Trefwoorden
review ige
Metriek

Beschrijving

Type I hypersensitivity (allergic reaction) is an unsuitable or overreactive immune response to an allergen due to cross-link immunoglobulin E (IgE) antibodies bound to its high-affinity IgE receptors (FcεRIs) on effector cells.

It is needless to say that at least two epitopes on allergens are required to the successful and effective cross-linking.

There are some reports pointing to small proteins with only one IgE epitope could cross-link FcεRI-bound IgE through homo-oligomerization which provides two same IgE epitopes.

Therefore, oligomerization of allergens plays an indisputable role in the allergenic feature and stability of allergens.

In this regard, we review the signaling capacity of the B cell receptor (BCR) complex and cross-linking of FcεRI which results in the synthesis of allergen-specific IgE.

This review also discusses the protein-protein interactions involved in the oligomerization of allergens and provide some explanations about the oligomerization of some well-known allergens, such as calcium-binding allergens, Alt a 1, Bet v 1, Der p 1, Per a3, and Fel d 1, along with the effects of their concentrations on dimerization.

Hasan-Abad, Amin Moradi,Mohammadi, Mohsen,Mirzaei, Hamed,Mehrabi, Mohsen,Motedayyen, Hossein,Arefnezhad, Reza, 2022, Impact of oligomerization on the allergenicity of allergens, BioMed Central

Delen

Bron

Artikelen aanbevolen door ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw